Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report.

Cancer treatment and research communications - 1 Jan 2024

Illini Oliver, Lang-Stöberl Anna Sophie, Fabikan Hannah, Weinlinger Christoph, Valipour Arschang, Hochmair Maximilian J

Abstract excerpt

INTRODUCTION: Treatment options for HER2-mutant patients with non-small cell lung cancer (NSCLC) are limited. New agents, including zongertinib, a HER2-selective tyrosine kinase inhibitor (TKI), are being investigated in clinical trials. However, published clinical data on the efficacy and safety of zongertinib are limited to data from a single phase I trial including only 36 patients with NSCLC. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyridines

Share to Quinolines

Source

Identifiers

PMID: 39904276
DOI: 10.1016/j.ctarc.2025.100875

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report.PMID 39904276Read ↗

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

The development of Zongertinib for HER2-mutant NSCLCSemantic proximity Read ↗

Zongertinib: First Approval.Semantic proximity Read ↗

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.Semantic proximity Read ↗

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.Semantic proximity Read ↗

Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation.Semantic proximity Read ↗

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.Semantic proximity Read ↗

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.Semantic proximity Read ↗

Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.Semantic proximity Read ↗

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.